This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News for ACRV
Verastem (VSTM) Begins Dosing in Solid Tumors Study in China
AbbVie (ABBV) Files for Rinvoq in Giant Cell Arteritis in US & EU
ACRV: What are Zacks experts saying now?
Zacks Private Portfolio Services
SpringWorks (SWTX) Rises More Than 40% in a Year: Here's Why
Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up
Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion
Other News for ACRV
Acrivon Therapeutics, Inc.: A Promising Buy Amidst Clinical Advancements and Robust Pipeline Developments
Acrivon Therapeutics, Inc.: A Strong Buy on Robust Clinical Prospects and Financial Stability
ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q2 2024
Promising Acrivon Trial Results and Market Opportunity Support Buy Rating
Buy Rating Affirmed on Acrivon Therapeutics Amid Anticipated Clinical Updates and Novel Treatment Approaches